目的 探讨清脑降压片联合非洛地平缓释片治疗原发性高血压的临床疗效。方法 选取2015年2月-2016年2月在上海市静安区石门二路街道社区卫生服务中心接受治疗的原发性高血压患者94例,按照治疗方法的差别将所有患者分成对照组和治疗组,每组各47例。对照组口服非洛地平缓释片,10mg/次,1次/d。治疗组在对照组治疗的基础上口服清脑降压片,6片/次,3次/d。两组均连续治疗4周。观察两组的临床疗效,同时比较治疗前后两组舒张压(DBP)、收缩压(SBP)、脑利钠肽(NT-ProBNP)、同型半胱氨酸(HCY)的变化情况。结果 治疗后,对照组和治疗组的总有效率为82.98%、95.74%,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者SBP、DBP、HCY、NT-ProBNP均显著降低,同组治疗前后差异有统计学意义(P<0.05);且治疗组这些观察指标的改善程度优于对照组,两组比较差异有统计学意义(P<0.05)。结论 清脑降压片联合非洛地平缓释片治疗原发性高血压具有较好的临床疗效,可明显降低血清HCY、NT-ProBNP水平,具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Qingnao Jiangya Tablets combined with Felodipine Sustained Release Tablets in treatment of primary hypertension. Methods Patients (94 cases) with primary hypertension in Shimen Two-Way Street Community Health Service Center of Jing'an District in Shanghai from February 2015 to February 2016 were enrolled in this study. According to the different treatment plans, patients were divided into control group (47 cases) and treatment group (47 cases). The patients in the control group were po administered with Felodipine Sustained Release Tablets, 10 mg/time, once daily. The patients in the treatment group were po administered with Qingnao Jiangya Tablets on the basis of control group, 6 tablets/time, three times daily. The patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and the changes of DBP, SBP, NT-ProBNP, and HCY in two groups were compared before and after treatment. Results After treatment, the efficacies in the control and treatment groups were 82.98% and 95.74%, respectively, and there were differences between two groups (P < 0.05). After treatment, SBP, DBP, HCY, and NT-ProBNP in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Qingnao Jiangya Tablets combined with Felodipine Sustained Release Tablets has clinical curative effect in treatment of primary hypertension, and can significantly reduce serum HCY, NT-ProBNP, which has a certain clinical application value.